The Role of Serum Adhesion Molecules and Vascular Endothelial Growth Factor in the Treatment Approach of the Lung Cancer Patients

1
The Role of Serum Adhesion Molecules and Vascular
Endothelial Growth Factor in the Treatment
Approach of the Lung Cancer Patients

• AHMET SELIM YURDAKUL1, ELIF REYHAN HAN1,
• NESLIHAN BUKAN2 CAN ÖZTÜRK1
• 1- Gazi University Faculty of Medicine
• Department of Pulmonary Medicine
• 2- Gazi University Faculty of Medicine
• Department of Biochemistry

2
INTRODUCTION

• Lung cancer is the most frequent cause of cancer
  death among malignant diseases.
• Among the pulmonary carcinomas, non-small cell
  lung cancer (NSCLC) accounts for more than 75
  percent.
• High percentage of distant metastases was
  determined at the time of diagnosis of NSCLC.

3
INTRODUCTION

• Neovascularisation is a requirement for the
  growth and metastasis of solid tumours.
• Vascular endothelial growth factor (VEGF),
  matrix metalloproteinases (MMP) and soluble
  intercellular adhesion molecule (sICAM) are most
  potent factors involved in angiogenesis.

4
AIM

• The aim of this study was to analyse the
  association of pretreatment serum levels of
  MMP-9, MMP-13, VEGF and sICAM with clinical
  parameters and survival in patients with
  non-small-cell lung cancer (NSCLC).

5
METHOD

• Serum levels of MMP-9, MMP-13, VEGF and sICAM
  were analysed in 72 patients with NSCLC patients
  (mean age60.0310.86) and 46 healthy controls
  (mean age 61.1314.71). The analysis was
  performed by enyzme-linked immunosorbent assay
  (ELISA).

6
RESULTS
Table 1. Relationship between survival time and
stage, ECOG PS, lymph node and distant metastases
N Median survival time (month) P value
Stage I/II III IV 16 35 21 27 24 6 lt0.05
ECOG PS 0 1 2-4 50 14 8 24 15 3 lt0.05
Lymph node metastases Yes No 53 19 15 24 lt0.05
Distant metastases Yes No 51 21 6 27 lt0.05
7
RESULTS
Table 2. Levels of MMP-9, MMP-13, VEGF and
sICAM-1 in patients and control groups
Parameters Patient Control group P value
MMP-9 (pg/ml) 5148.21996.2 2943.6851.7 Plt0.05
MMP-13 (ng/ml) 0.460.48 0.531.35 Pgt0.05
VEGF (pg/ml) 248.7255.9 182.1207.5 Plt0.05
sICAM-1 (ng/ml) 985.0489.4 300.5204.1 Plt0.05
8
RESULTS
Table 3. Levels of MMP-9, MMP-13, VEGF and
sICAM-1 in patients with NSCLC before and after
treatment
Parameters Before treatment After treatment P value
MMP-9 (pg/ml) 5037.22190.8 3202.2828.9 Plt0.05
MMP-13 (ng/ml) 0.530.41 1.162.01 Pgt0.05
VEGF (pg/ml) 184.6213.0 128.946.6 Pgt0.05
sICAM-1 (ng/ml) 826.9551.5 253.9113.5 Plt0.05
9
RESULTS
Table 4. sICAM-1, VEGF, MMP-9 and MMP-13 levels
according to stages of disease in patients with
NSCLC
Evre sICAM-1 VEGF MMP-9 MMP-13
I/II 726.3 513.7 168.2 178 5380.5 1671.5 0.56 0.41
III 1067.0 406.2 275.8 280.9 4925.9 2159.1 0.45 0.58
IV 1053.2 543 267.3 263 5320.5 2009.3 0.39 0.32
10
CONCLUSION

• High levels of MMP-9, VEGF and sICAM were found
  in NSCLC patients.
• Analyse of serum levels of MMP-9, VEGF and sICAM
  appears to be a potentially tumor marker.